The PTRG-DES consortium is a coalition composed of multi-center, real-world registries including CAD patients treated with DES in South Korea. From 9 academic registries in Korea, a total of 13,160 patients were enrolled for this database between July 2003 and August 2018. The aim of the study was to investigate long-term prognostic implications of platelet function and genotypes after DES implantation for significant CAD in South Korea.

The investigators enrolled patients treated with DES during DAPT including clopidogrel who had at least one of VerifyNow test (PRU and ARU) and genotyping. In this consortium, the investigators tried to find the unique characteristics of East Asians based on platelet function, genotype and inflammatory markers.

Inclusion Criteria:

• Consecutive patients at every centre successfully treated with one or more DES approved by the US FDA or CE mark and who were adequately loaded with clopidogrel were eligible for enrolment, regardless of patient or lesion complexity.

Exclusion Criteria:

• the occurrence of a major complication during the procedure or before platelet function testing, or if bypass surgery was planned after PCI.
• Any P2Y12 inhibitor other than clopidogrel
• PCI strategy other than DES
• Needed oral anticoagulant (e.g. atrial fibrillation)

Significant CAD patients treated with uneventful DES implantation

If there are the chances of collaboration work, we will share IPD with other groups.